Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TAKHZYRO® safely and effectively. See full prescribing information for TAKHZYRO. TAKHZYRO (lanadelumab-flyo) injection, for subcutaneous useInitial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
TAKHZYRO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.
- generic_name
- lanadelumab-flyo
- product_names
- lanadelumab-flyo
- ndc
- 47783-646, 47783-646-01, 47783-644, 47783-644-01, 47783-645, 47783-645-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en